Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Firsov

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|October 31, 1998
A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesA A Firsov, S N Vostrov, A A Shevchenko, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|May 1, 1985
[Pharmacokinetics of sisomicin during hemosorption and hemodialysis]A A Firsov, O S Treskina, L V Umnova, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|June 1, 1992
[Age-related characteristics of ceftazidime pharmacokinetics in children]P I Prokhorenko, L S Strachunskiĭ, E G Andreenkova, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|March 1, 1985
[Decrease of sisomicin nephrotoxicity as affected by cephalothin: pharmacokinetic evaluation]E V Gagaeva, A A Firsov, G G Egorenko, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|November 1, 1986
[Pharmacokinetics of cefazolin during hemosorption and hemodialysis]A A Firsov, O S Treskina, V N Nasonov, et al.
Diagnostic Microbiology and Infectious Disease|September 29, 2001
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationshipsS H Zinner, S N Vostrov, I Y Lubenko, et al.
Antimicrobial Agents and Chemotherapy|October 31, 1998
MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic modelA A Firsov, S N Vostrov, A A Shevchenko, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1999
Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic modelA A Firsov, R G Vasilov, S N Vostrov, et al.
The Journal of Antimicrobial Chemotherapy|November 4, 2000
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient dosesA A Firsov, I Y Lubenko, S N Vostrov, et al.
Nature|November 18, 2005
Nanofabricated media with negative permeability at visible frequenciesA N Grigorenko, A K Geim, H F Gleeson, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|October 31, 1998
A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesA A Firsov, S N Vostrov, A A Shevchenko, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|May 1, 1985
[Pharmacokinetics of sisomicin during hemosorption and hemodialysis]A A Firsov, O S Treskina, L V Umnova, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|June 1, 1992
[Age-related characteristics of ceftazidime pharmacokinetics in children]P I Prokhorenko, L S Strachunskiĭ, E G Andreenkova, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|March 1, 1985
[Decrease of sisomicin nephrotoxicity as affected by cephalothin: pharmacokinetic evaluation]E V Gagaeva, A A Firsov, G G Egorenko, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|November 1, 1986
[Pharmacokinetics of cefazolin during hemosorption and hemodialysis]A A Firsov, O S Treskina, V N Nasonov, et al.
Diagnostic Microbiology and Infectious Disease|September 29, 2001
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationshipsS H Zinner, S N Vostrov, I Y Lubenko, et al.
Antimicrobial Agents and Chemotherapy|October 31, 1998
MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic modelA A Firsov, S N Vostrov, A A Shevchenko, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1999
Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic modelA A Firsov, R G Vasilov, S N Vostrov, et al.
The Journal of Antimicrobial Chemotherapy|November 4, 2000
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient dosesA A Firsov, I Y Lubenko, S N Vostrov, et al.
Nature|November 18, 2005
Nanofabricated media with negative permeability at visible frequenciesA N Grigorenko, A K Geim, H F Gleeson, et al.
Pageof 11